NCT00631579View on ClinicalTrials.gov

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions
HyperuricemiaLeukemiaLymphoma
Interventions
DRUG

Rasburicase (SR29142)

Trial Locations (1)

Unknown

Sanofi-Aventis, Tokyo

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00631579 - Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma | Biotech Hunter | Biotech Hunter